Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2011;6(11):e27622.
doi: 10.1371/journal.pone.0027622. Epub 2011 Nov 15.

I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe

Esther Kissling  1 , Marta Valenciano, Jean Marie Cohen, Beatrix Oroszi, Anne-Sophie Barret, Caterina Rizzo, Pawel Stefanoff, Baltazar Nunes, Daniela Pitigoi, Amparo Larrauri, Isabelle Daviaud, Judit Krisztina Horvath, Joan O'Donnell, Thomas Seyler, Iwona Anna Paradowska-Stankiewicz, Pedro Pechirra, Alina Elena Ivanciuc, Silvia Jiménez-Jorge, Camelia Savulescu, Bruno Christian Ciancio, Alain Moren
Affiliations
Multicenter Study

I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe

Esther Kissling et al. PLoS One. 2011.

Abstract

Background: In the third season of I-MOVE (Influenza Monitoring Vaccine Effectiveness in Europe), we undertook a multicentre case-control study based on sentinel practitioner surveillance networks in eight European Union (EU) member states to estimate 2010/11 influenza vaccine effectiveness (VE) against medically-attended influenza-like illness (ILI) laboratory-confirmed as influenza.

Methods: Using systematic sampling, practitioners swabbed ILI/ARI patients within seven days of symptom onset. We compared influenza-positive to influenza laboratory-negative patients among those meeting the EU ILI case definition. A valid vaccination corresponded to > 14 days between receiving a dose of vaccine and symptom onset. We used multiple imputation with chained equations to estimate missing values. Using logistic regression with study as fixed effect we calculated influenza VE adjusting for potential confounders. We estimated influenza VE overall, by influenza type, age group and among the target group for vaccination.

Results: We included 2019 cases and 2391 controls in the analysis. Adjusted VE was 52% (95% CI 30-67) overall (N = 4410), 55% (95% CI 29-72) against A(H1N1) and 50% (95% CI 14-71) against influenza B. Adjusted VE against all influenza subtypes was 66% (95% CI 15-86), 41% (95% CI -3-66) and 60% (95% CI 17-81) among those aged 0-14, 15-59 and ≥60 respectively. Among target groups for vaccination (N = 1004), VE was 56% (95% CI 34-71) overall, 59% (95% CI 32-75) against A(H1N1) and 63% (95% CI 31-81) against influenza B.

Conclusions: Results suggest moderate protection from 2010-11 trivalent influenza vaccines against medically-attended ILI laboratory-confirmed as influenza across Europe. Adjusted and stratified influenza VE estimates are possible with the large sample size of this multi-centre case-control. I-MOVE shows how a network can provide precise summary VE measures across Europe.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have the following competing interest: E. Kissling, M. Valenciano, T. Seyler, C. Savulescu and A. Moren are employees of EpiConcept, Paris. J.M. Cohen and I. Daviaud are employees of GROG/Open Rome, Paris. As Head of Open Rome, J.M. Cohen is involved in several epidemiological studies that are partially or fully funded by pharmaceutical companies (Sanofi-Pasteur, GSK, Roche), nonprofit organizations (Mutuelles, Résaeu DES France) or public institutions (ECDC, CU Strasbourg). He is a member of Association Mieux Prescrire and the advisory boards of Novartis, Roche, and Wyeth (free participation, no compensation). During the past five years, he has received travel grants from Sanofi-Pasteur and Roche. I. Daviaud is involved, through the other institution with which she is affiliated and salaried (Open Rome research department), in the coordination or analysis of epidemiological studies partially or fully funded by Roche and GSK. EpiConcept conducted for the Mexican Social Security and GSK an evaluation of the Mexican hospital based surveillance system for intussusceptions (2008). EpiConcept coordinated studies for measuring influenza vaccine effectiveness funded by EVM, the association of the European Vaccine Manufacturers. None of the current authors were involved in these studies (2009). EpiConcept conducts for SP-MSD the data analysis of a study conducted in Finland to measure the impact of rotavirus vaccination on hospitalisation for acute gastroenteritis due to rotavirus infection (2009-10). There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials. All other authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Influenza-like illness/Acute Respiratory Infection rates by week as reported by the National Sentinel systems, I-MOVE multi-centre case control study, influenza season 2010-11.
Figure 2
Figure 2. Flowchart of data exclusion for pooled analysis, I-MOVE multi-centre case control study, influenza season 2010-11.
Figure 3
Figure 3. ILI patients influenza positive (N = 2019), A(H1N1)2009 positive (N = 1179), B positive (N = 765) and influenza negative (N = 2391) by week of symptom onset, I-MOVE multi-centre case control study, influenza season 2010-11.
See this image and copyright information in PMC

References

    1. European Commission. 2009. Proposal for a Council recommendation on seasonal influenza vaccination. 353/final/2. Available from: http://ec.europa.eu/health/ph_threats/com/Influenza/docs/seasonflu_rec20.... Accessed October 2011.
    1. Mereckiene J, Cotter S, D'Ancona F, Giambi C, Nicoll A, et al. Differences in national influenza vaccination policies across the European Union, Norway and Iceland 2008-2009. Euro Surveill. 2010;15 - PubMed
    1. Valenciano M, Ciancio B, Moren A. First steps in the design of a system to monitor vaccine effectiveness during seasonal and pandemic influenza in EU/EEA Member States. Euro Surveill. 2008;13:19015. - PubMed
    1. Kissling E, Valenciano M, Falcao J, Larrauri A, Widgren K, et al. “I-MOVE” towards monitoring seasonal and pandemic influenza vaccine effectiveness: lessons learnt from a pilot multi-centric case-control study in Europe, 2008-9. Euro Surveill. 2009;14 - PubMed
    1. Valenciano M, Kissling E, Cohen JM, Oroszi B, Barret AS, et al. Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study. PLoS Med. 2011;8:e1000388. - PMC - PubMed

Publication types

MeSH terms

Substances